GIC
REGN icon

Generali Investments CEE’s Regeneron Pharmaceuticals REGN Stock Holding History

Generali Investments CEE’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Buy
2,370
+200
+9% +$136K 0.07% 240
2026
Q1 		$1.68M Hold
2,170
– – 0.09% 227
2025
Q4 		$1.67M Hold
2,170
– – 0.12% 195
2025
Q3 		$1.22M Hold
2,170
– – 0.09% 221
2025
Q2 		$1.14M Buy
2,170
+540
+33% +$301K 0.09% 215
2025
Q1 		$1.03M Hold
1,630
– – 0.1% 218
2024
Q4 		$1.16M Buy
+1,630
New +$1.37M 0.12% 193

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Generali Investments CEE's REGN Position: Q2 2026 in Review

Generali Investments CEE increased its Regeneron Pharmaceuticals (REGN) stake by 9.2% in Q2 2026, buying an estimated $136K and bringing the position to 2,370 shares worth $1.48M. The position accounts for 0.07% of the portfolio, ranked #240.

Generali Investments CEE first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.68M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Generali Investments CEE held 2,370 shares of Regeneron Pharmaceuticals worth $1.48M as of Q2 2026.
  • Generali Investments CEE bought 200 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $136K.
  • Regeneron Pharmaceuticals made up 0.07% of Generali Investments CEE's portfolio in Q2 2026, its #240 holding.
  • Generali Investments CEE first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Generali Investments CEE's Regeneron Pharmaceuticals position peaked at $1.68M in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Generali Investments CEE's 13F filing for Q2 2026, filed 13 Jul 2026.